Taken together, our data revealed that inhibition of SAAL1 could increase the chemosensitivity of HCC cells towards sorafenib or foretinib treatment, and SAAL1 siRNA may exert synergistic effects with sorafenib or foretinib in the treatment of HCC. The gene discussed is SAAL1; the disease is hepatocellular carcinoma.